Report overview
Wilson?s disease is also known as progressive lenticular degeneration and hepatolenticular degeneration that causes copper poisoning in the body. Copper is a necessary element for cellular functions; however, excessive copper is extremely toxic and can cause permanent damage to cellular functions of body. Wilson?s disease is caused by excessive deposition of copper in the body. Generally, copper is released into bile from the diet is cleaned out by the liver, flowing out of the body from the gastrointestinal tract. Wilson?s disease occurs due to excessive deposition of copper in the brain, liver, and other tissues of the body. According to the American Association for the Study of Liver Diseases, Wilson?s disease occurs worldwide with prevalence of approximately 30 individuals affected per million.
This report aims to provide a comprehensive presentation of the global market for Wilson's Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wilson's Disease Drugs. This report contains market size and forecasts of Wilson's Disease Drugs in global, including the following market information:
Global Wilson's Disease Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Wilson's Disease Drugs market was valued at US$ 210 million in 2022 and is projected to reach US$ 308.5 million by 2029, at a CAGR of 5.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of Wilson?s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson?s disease. Penicillamine is the most successful drug used for the treatment of Wilson?s disease. Wilson?s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson?s disease is Drugs?Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
We surveyed the Wilson's Disease Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Wilson's Disease Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Wilson's Disease Drugs Market Segment Percentages, by Type, 2022 (%)
Hepatic
Neuropsychiatric
Ophthalmic
Others
Global Wilson's Disease Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Wilson's Disease Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinic
Others
Global Wilson's Disease Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Wilson's Disease Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Wilson's Disease Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Wilson's Disease Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Wilson's Disease Drugs, market overview.
Chapter 2: Global Wilson's Disease Drugs market size in revenue.
Chapter 3: Detailed analysis of Wilson's Disease Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Wilson's Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
